Blood components separator disk
Abstract
A separator disk for use in centrifugal separation of components is designed to automatically position itself during separation at the interface between the supernatant and the remaining components. Preferably the interface is between plasma and red blood cells.

Term
Term ended
Expired 27 April 2021, 5.4 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
11 claims: 1 independent, 10 dependent
- 1Apparatus for use in the separation of the components of different specific gravities of a fluid, comprising a container with an interior surface which defines a chamber (2) adapted to contain such a fluid to be subjected to centrifugation and a separator disk (4) adapted to float in the fluid at an interface between those components when the fluid is centrifuged in the container, the separator disk (4) being made of a material having a specific gravity just less than the specific gravity of the lower component characterised in that the shape and specific gravity of the separator disk (4) are such that it has an upper surface which, when the fluid is centrifuged in the container, is just below the interface to allow a small layer of the lower component to form on the upper surface.
23 paragraphs, as filed
This invention relates to methods and apparatus for use in the separation of fluids into components having different specific gravities. The invention finds special utility in the centrifugal separation of the components of blood.
Centrifugal separation of blood into components of different specific gravities, such as red blood cells, white blood cells, platelets, and plasma is known from <patcit id="pcit0001" dnum="US5707331A"><text>United States Patent 5,707,331 (Wells</text></patcit>). The apparatus shown in that patent employs a disposable processing tube having two chambers, and blood to be separated into components is placed in one of the chambers. The processing tube is placed in a centrifuge, which subjects the blood to centrifugal forces to separate the components. The supernatant is then automatically decanted into the second of the chambers.
To retain, principally, the red blood cells during the decant of the supernatant, the apparatus disclosed in the Wells patent includes a shelf placed in the first chamber at the expected level of the interface between the red blood cells and the less-dense components, including the plasma. One problem with the arrangement shown in the '331 Wells patent, however, is that the position of the interface varies with the particular proportions of the components (e.g. the hematocrit) of the blood to be processed. Thus, if the shelf is placed at the expected position of the interface for blood of average hematocrit, and the hematocrit of the particular blood being processed is low, the shelf will be above the interface after separation. Such a position of the shelf will hinder the flow of the components near the interface during decanting, thus retaining significant amounts of these components in the first chamber and reducing the separation efficiency of the system.
In <patcit id="pcit0002" dnum="US5632905A"><text>US-A-5632905</text></patcit>, a blood sample is gravimetrically separated into its heavier and lighter phases by centrifugation in a tube. The phases are separated by a disc which has a center of buoyancy and a center of mass that are spaced apart from each other along the axis of symmetry of the disc. The diameter of the disc is slightly larger than the bore diameter of the tube. The disc is initially positioned in the tube with its axis of symmetry perpendicular to the axis of the tube so that blood drawn into the tube can readily pass by the disc. Upon centrifugation, the disc will tumble through a 90° angle so that the axis of symmetry of the disc will be coincidental with the axis of the tube. Once the disc has tumbled in the sample, the ongoing centrigual forces will cause a stretching of the disc along its axis of symmetry thereby decreasing the diameter of the disc. The stretching forces exerted on the disc will temporarily decrease the effective specific gravity of the disc so that the disc will remain in the upper portion of the lighter phase of the sample during the initial portion of the centrifugation. As the centrifuge slows down, the disc sinks through the lighter phase of the sample and settles on the interface between the lighter and heavier phases of the sample, thereby separating the two phases of the sample. One of the phases can then be removed from the tube without contamination from the other phase.
<patcit id="pcit0003" dnum="US3972812A"><text>US-A-3972812</text></patcit> discloses an impregnated porous disc made of an inert material with voids adapted for insertion into a collection tube containing clotted blood which disc upon centrifugation of the tube will allow separation of fibrin and cellular material from the serum by centrifugal force during its controlled descent through the serum and will stop when it hits the serum-clot interface to isolate the serum from the clot.
The present invention is directed to apparatus for use in the separation of the components of different specific gravities of a fluid, comprising a container with an interior surface which defines a chamber adapted to contain such a fluid to be subjected to centrifugation and a separator disk adapted to float in the fluid at an interface between those components when the fluid is centrifuged in the container, the separator disk being made of a material having a specific gravity just less than the specific gravity of the lower component characterised in that the shape and specific gravity of the separator disk are such that it has an upper surface which, when the fluid is centrifuged in the container, is just below the interface to allow a small layer of the lower component to form on the upper surface.
The present invention extends to a method of separating plasma from red blood cells comprising the steps of: <ol id="ol0001" compact="compact" ol-style=""><li>(i) providing apparatus as set out in the immediately preceding paragraph;</li><li>(ii) introducing blood into the chamber; and</li><li>(iii) centrifuging the chamber.</li></ol>
In accordance with the invention, a movable separator disk, which automatically positions itself at the interface between the separated components, is placed in the first chamber. In the preferred embodiment, the disk is capable of moving vertically and is designed to position itself automatically at the interface between red blood cells and the remaining components in the centrifugal separation of blood.
Decant of the supernatant can be either by gravity drain or by centrifugal transfer, and a main function of the disk is to restrict the flow of the component below it, e.g. red blood cells, during decant. This ensures that the supernatant is not contaminated and increases the efficiency of the process.
The invention contemplates two embodiments for the disk. In one embodiment, the disk is supported on a central shaft such that an annulus is formed between the perimeter of the disk and the interior surface of the first chamber. The dimensions of the annulus are such that the flow of red blood cells through it during decant is restricted such that they do not contaminate the decanted supernatant to any significant degree.
In another embodiment, the disk is arranged on the shaft such that, when the chamber is tilted for gravity decanting, the disk rotates such that one edge of the disk engages the wall of the chamber to block flow of red blood cells.
In either of these embodiments, the specific gravity of the disk and its shape may be chosen so that a major part of the upper surface lies just below the interface, thus facilitating release of the supernatant from the disk during decanting. This upper surface is also preferably curved to match the cylindrical shape the interface assumes during centrifugation. <ul id="ul0001" list-style="none" compact="compact"><li>Figure la is a longitudinal cross-section of a portion of a processing tube chamber and a separator disk not embodying the present invention;</li><li>Figure 1b is a transverse cross-section taken along line 1b-1b of Figure 1a;</li><li>Figure 2a is a longitudinal cross-section of the construction of Figures 1a and 1b when the separator disk is tilted during decanting;</li><li>Figure 2b is a transverse cross-section taken along line 2b-2b of Figure 2a;</li><li>Figure 3a is a longitudinal cross-section of a further construction not embodying the present invention;</li><li>Figure 3b is a transverse cross-section taken along the line 3b-3b of Figure 3a;</li><li>Figure 4 is a longitudinal cross-section of a processing tube chamber and a separator disk which does embody the present invention.</li></ul>
With reference to Figures 1 and 2, one chamber 2 of a processing tube, such as that shown in the '331 Wells patent has a separator disk 4 supported therein by a central shaft 6. The shaft 6 is designed to direct fluid introduced into the chamber to the bottom of the chamber. This precludes the formation of an air bubble at the bottom of the chamber, especially when the bottom of the chamber is tapered. Thus, fluid is introduced into the chamber by inserting a cannula attached to a syringe containing blood into the shaft 6 and discharging the blood from the syringe into the chamber. A central opening 8 in the disk receives the shaft 6 in such a manner that the disk easily slides along the shaft.
The shaft 6 may not be necessary in all instances, for example, when the bottom of the processing tube is flat. In that instance the disk does not have a central hole.
The disk is preferably made of material having a specific gravity that allows the disk to float at the interface with red blood cells. Preferably that specific gravity is about 1.04 (e.g. polystyrene), which is just less than the specific gravity of red blood cells at 70% hematocrit. Thus, when the blood is centrifuged, the disk moves to the interface between the red blood cells and the other components.
The interface will naturally assume a cylindrical shape with a cylindrical radius equal to the distance to the center of rotation of the centrifuge. The disk may be cylindrical, to match the shape of the interface.
In Figures 1a, 1b, 2a and 2b, the diameters of the hole 8 and the shaft 6 are such that an annular gap 10 is formed between the outer surface of the shaft and the interior surface of the hole 8. Similarly, an annular gap 12 is provided between the perimeter of the disk and the interior surface of the tube 2.
Figures 1a and 1b illustrate the position of the disk during centrifugation, and it will be appreciated that the gaps 10 and 12 are large enough to allow passage of the descending heavier components, e.g. red blood cells and the ascending lighter components, e.g. plasma. However, the diameter of the central opening 8 is large enough whereby during decanting the disk 4 rotates as shown in the Figures. Thus, when the processing tube is rotated to the decant position, the more dense red blood cells, illustrated at 14, that have accumulated below the disk exert a force against the bottom of the disk as they try to flow through the gap 12. This causes the disk 4 to rotate, as shown in Figures 2a and 2b, until a portion of the lower outer edge 16 of the disk and also the upper outer edge 18 engage the inner surface of the chamber 2. This engagement between the edge 16 of the disk and the interior of the chamber effectively forms a valve that prevents flow of the red blood cells, allowing decant of the plasma supernatant without contamination by red blood cells. It will be appreciated that this construction requires the transverse dimension of the disk between edges 16 and 18 to be greater than the internal diameter of the tube so that the edges engage the interior of the tube when tilted.
A second construction is shown in Figures 3a and 3b. According to this construction, the gap 10 is made to be small whereby the disk does not rotate appreciably during decant, in contrast to the construction of Figures 1 and 2. It will be appreciated that an annular channel is formed by the gap 12, this channel having a width equal to the radial dimension of the gap and a length equal to the thickness of the disk at the edge. The rate of flow of a fluid through this channel is a function of the dimensions of the channel, and the dimensions of the disk of this construction are such that the red blood cells will not flow appreciably through the channel at 1G. Preferably the width of the gap is about 0.005 inch to about 0.020 inch, and the length is about 0.1 inch to about 0.3 inch.
Thus, the components of the blood flow through the channel during centrifugation (i.e. at 1000G), but do not flow appreciably through the channel during decanting at 1G. This allows the supernatant to be decanted without significant contamination by the red blood cells
Figure 4 illustrates a preferred shape of the disk 4 which, in combination with the other parts shown in Figures 1 to 3, constitutes an embodiment of the present invention. In this embodiment, the top surface 20 of the disk is concave, preferably cylindrical, and the disk is provided with an elongated central portion 22. The specific gravity of the disk material is selected so that the concave surface 20 is located just below the interface. That is, the thickness of the outer edge, the length of the portion 22, and the specific gravity of the material are chosen so that the center of buoyancy of the disk is just above the concave surface, and that surface will be just below the interface 26 with red blood cells. This arrangement allows a small layer 24 of the red blood cells to form on the upper surface.
The layer of red blood cells 24 reduces the surface tension between the platelets at the interface 26 and the surface 20 of the disk and facilitates release of the platelets from the disk. This is important to ensure that all of the platelets are decanted, and the small amount of red blood cells that may be decanted along with the supernatant does not generally represent a significant contamination of the supernatant.
Modifications within the scope of the appended claims will be apparent to those of skill in the art.
4 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US9919308B2 | Cited by | United States of America | Applicant |
| US11786895B2 | Cited by | United States of America | Applicant |
| US9933344B2 | Cited by | United States of America | Applicant |
| US12090476B2 | Cited by | United States of America | Applicant |
| US11351535B2 | Cited by | United States of America | Applicant |
| US9700886B2 | Cited by | United States of America | Applicant |
| US11660603B2 | Cited by | United States of America | Applicant |
| US9272083B2 | Cited by | United States of America | Applicant |
| US9919307B2 | Cited by | United States of America | Applicant |
| US11278884B2 | Cited by | United States of America | Applicant |
| US10603665B2 | Cited by | United States of America | Applicant |
| US10005081B2 | Cited by | United States of America | Applicant |
| US9694359B2 | Cited by | United States of America | Applicant |
| US9731290B2 | Cited by | United States of America | Applicant |
| US9919309B2 | Cited by | United States of America | Applicant |
| US10807088B2 | Cited by | United States of America | Applicant |
| US12109566B2 | Cited by | United States of America | Applicant |
| US11759777B2 | Cited by | United States of America | Applicant |
| US9802189B2 | Cited by | United States of America | Applicant |
| US9714890B2 | Cited by | United States of America | Applicant |
| US280820A | Cites | United States of America | – |
| US593333A | Cites | United States of America | – |
| US3409165A | Cites | United States of America | – |
| US3929646A | Cites | United States of America | – |
| US3972812A | Cites | United States of America | – |
| US4417981A | Cites | United States of America | – |
| US5632905A | Cites | United States of America | – |
| US5736033A | Cites | United States of America | – |
34 members in 14 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 200150P | United States of America | – | |
| 20015000 | United States of America | P | |
| 20015000 | United States of America | P | |
| 0111732 | United States of America | W | |
| 0111732 | United States of America | W | |
| 200150P | – | – | – |
| US20000200150P | – | – | – |
| US2001011732 | – | – | – |
| WO2001US11732 | – | – | – |
Members34
| Document | Office | Kind | |
|---|---|---|---|
| CA2407346A1 | Canada | A1 | |
| WO0183068A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7208501A | Australia | A | |
| US2003010711A1 | United States of America | A1 | |
| EP1289618A1 | European Patent Office (EPO) | A1 | |
| EP1289618A4 | European Patent Office (EPO) | A4 | |
| CN1441690A | China | A | |
| JP2003531704A | Japan | A | |
| HK1059059A1 | Hong Kong, China | A1 | |
| US2006032825A1 | United States of America | A1 | |
| AU2001272085B2 | Australia | B2 | |
| US7077273B2 | United States of America | B2 | |
| CN1309442C | China | C | |
| EP1289618B1This record | European Patent Office (EPO) | B1 | |
| AT382408T | Austria | T | |
| ATE382408T1 | Austria | T1 | |
| DE60132198D1 | Germany | D1 | |
| PT1289618E | Portugal | E | |
| DK1289618T3 | Denmark | T3 | |
| ES2298234T3 | Spain | T3 | |
| JP4128007B2 | Japan | B2 | |
| DE60132198T2 | Germany | T2 | |
| US7547272B2 | United States of America | B2 | |
| CA2407346C | Canada | C | |
| US2009283524A1 | United States of America | A1 | |
| USRE43547E | United States of America | E | |
| CY1107189T1 | Cyprus | T1 | |
| US2013079212A1 | United States of America | A1 | |
| US2014131292A1 | United States of America | A1 | |
| US2015290661A1 | United States of America | A1 | |
| US9393575B2 | United States of America | B2 | |
| US9393576B2 | United States of America | B2 | |
| US2017008012A1 | United States of America | A1 | |
| US9656274B2 | United States of America | B2 |
77 legal events, as 13 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Notification of lapseLapsedST | ST | FR | |
| Lapse due to non-payment of feesLapsedML | ML | GR | |
| Lapse because of not paying annual feesLapsedMM01 | MM01 | AT | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed because of non-payment of the annual feeLapsedV1 | V1 | NL | |
| Ep patent lapsedLapsedEBP | EBP | DK | |
| Annulment/lapse due to non-payment of fees, searched and examined patentLapsedLAPSE DUE TO NON-PAYMENT OF FEESMM4A | MM4A | PT | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Change of the address of the representativeNEW ADDRESS: ZIMMERGASSE 16, 8008 ZUERICH (CH)PCAR | PCAR | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| MergerPFUS | PFUS | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Ep patent validated in greeceEP | EP | GR | |
| Definitive protectionFG2A | FG2A | ES | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A | SC4A | PT | |
| New agentNV | NV | CH | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Supplementary search report drawn up and despatchedA4 | A4 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1289618
- Publication, DOCDB
- 1289618
- Publication, EPODOC
- EP1289618
- Application
- 1930473
- Application, DOCDB
- 01930473
- Application, EPODOC
- EP20010930473
Titles3
- German
- PLATTENTRENNEINRICHTUNG FÜR BLUTBESTANDTEILE
- English
- BLOOD COMPONENTS SEPARATOR DISK
- French
- DISQUE SEPARATEUR DE COMPOSANTS SANGUINS
Classification
- CPC, 15
- B01D17/0217
- B04B7/12
- A61M1/029
- B01D21/2433
- B01L3/50215
- B01D21/262
- B01D2221/10
- G01N33/491
- A61M1/3693
- B01D21/26
- B04B7/00
- B04B11/00
- B01L3/5021
- B01L2300/0803
- B01L2300/0832
- IPC, 8
- B01B1 00
- B01L3 14
- G01N33 48
- A61M1 02
- A61M1 36
- B01D17 02
- B01D21 24
- B04B5 02
Designated states1
- Contracting states, 1
- Türkiye